Amylyx Pharmaceuticals (AMLX) Total Current Liabilities (2021 - 2026)

Amylyx Pharmaceuticals' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $16.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 10.96% year-over-year to $16.0 million in Q1 2026; TTM through Mar 2026 was $16.0 million, a 10.96% decrease from a year earlier, with the FY2025 full-year figure at $22.7 million, down 20.13% from the prior year.
• Total Current Liabilities eased to $16.0 million in Q1 2026 per AMLX's latest filing, from $22.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $91.6 million in Q1 2024 and bottomed at $16.0 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $32.6 million (2022), against an average of $42.7 million.
• Across the five-year window, Total Current Liabilities surged 167.93% in 2022 and plunged 80.43% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $46.6 million in 2022, then surged by 76.02% to $82.0 million in 2023, then tumbled by 65.38% to $28.4 million in 2024, then declined by 20.13% to $22.7 million in 2025, then slipped by 29.63% to $16.0 million in 2026.
• Per Business Quant, the three latest AMLX Total Current Liabilities figures stand at $16.0 million (Q1 2026), $22.7 million (Q4 2025), and $25.8 million (Q3 2025).